FREE ELECTRONIC LIBRARY - Dissertations, online materials

Pages:   || 2 | 3 | 4 | 5 |   ...   | 9 |

«Evaluation of the WHO Patient Safety Solutions Aides Memoir Prepared for the Patient Safety Programme of the World Health Organization Donna O. ...»

-- [ Page 1 ] --

Evaluation of the WHO Patient Safety

Solutions Aides Memoir

Prepared for the Patient Safety Programme

of the World Health Organization

Donna O. Farley, PhD, MPH

Evaluation Consultant

August 31, 2011

Table of Contents

Table of Contents

List of Figures

List of Tables

1. Introduction

The Inaugural Set of Patient Safety Solutions Aides Memoir

The Collaborative Network

Evaluation Aims and Approach

Questions Addressed by the Evaluation

Logic Model That Guided the Evaluation

Organization of This Report

2. Evaluation Methods

Data Collection Methods

Review of Existing Written Materials

Interviews with Key Informants

Survey of Member State Stakeholders

Power Calculations To Determine Target Survey Sample Size

Analysis of Data Collected

Description of the Development and Dissemination Processes

Analysis of Stakeholder Interview Results

Analysis of Stakeholder Survey Results

3. Findings: the Patient Safety Solutions Products

The Concept of Patient Safety Aides Memoir

Survey results

Interview Results on the Solutions Concept

Value of the Product to Users

Needs and Priorities of Countries

Responsiveness of the Solutions to Users’ Priorities

The Patient Safety Solutions Development Process

The Field Review for the Patient Safety Solutions

Interview Results on Development of the Solutions

Assessment of the Evidence Base

Survey Results

i Interview Results on the Evidence Base for the Solutions

The Patient Safety Solutions Written Products

Survey Results

Interview Results on the Written Products

Highlights of Findings Regarding the Solutions Products

4. Findings: Dissemination and Impacts of The Patient Safety Solutions Aides Memoir... 35 Availability and Distribution of the Products

Placement of Patient Safety Solutions on Websites

Translations into Other Languages

Interview Results on Availability of the Solutions Products

Dissemination Strategy and Implementation

Survey Results on the Dissemination Process

Interview Results on the Dissemination Process

Awareness of the Patient Safety Solutions

Survey Results on Awareness of the Solutions

Interview Results on Awareness of the Solutions

Use of the Patient Safety Solutions

Usage Reported by the Collaborative Network

Survey Results

Interview Results on Use of the Solutions

Highlights of Findings Regarding Dissemination and Impact

5. Summary and Suggestions for Action

1. How effective is the concept of patient safety solutions Aide memoirs?

2. What is the quality or scientific integrity of the developed Aide memoirs solutions?......55

3. How valuable are the Aide memoirs in terms of the product?

4. How effective and usable are the following specific components of the Aide memoirs for users in each of the three groups of countries?

5. What impact have the patient safety solutions Aide memoirs had in terms of aiding Member States achieve the objectives of improving patient safety:

6. How can the concept, value, quality and impact of the product be improved?.................58

ii List of Figures

Figure 3.1 Target Audiences Identified for the Patient Safety Solutions Identified by Survey Respondents (N=809)

Figure 3.2 Clinical Care Issues Identified by Survey Respondents As One of Their Country’s Five Top Patient Safety Priorities (N=881)

Figure 3.3 System Process Issues Identified by Survey Respondents As One of Their Country’s Five Top Patient Safety Priorities (N=881)

Figure 3.4 Patient Safety Solutions Rated by Survey Respondents As Extremely Relevant to Their Countries Priorities (N=826)

Figure 4.1 Assessments by Survey Respondents About Dissemination Effectiveness and WHO Office Support for Dissemination (N=441)

Figure 4.2 Assessments by Survey Respondents About the Usefulness of the Patient Safety Solutions to Organizations’ Improvement Strategies (N=317)

Figure 4.2 Estimates by Survey Respondents About How Many Other Organizations Have Used the Solutions (N=394)

iiiiv List of Tables

Table 2.1 Methods for Collecting Data To Address Each Set of Evaluation Questions.

.............. 7 Table 2.2 Profile of Individual Interviews Conducted for the Evaluation

Table 2.3 Power Calculations Used to Determine Targeted Sample Size per WHO Region.

...... 10 Table 2.4 Distribution of Stakeholder Survey Respondents by WHO Region

Table 2.5 Distribution of Stakeholder Survey Respondents by Type of Organization.

.............. 12 Table 2.6 Distribution of Stakeholder Survey Respondents by Health-Care Role

Table 3.1 Survey Respondents Assessments Regarding Roles of the Patient Safety Solutions

Table 3.2 Target Audiences for the Patient Safety Solutions Identified by Survey Respondents, by Region

Table 3.3 Level of Priority for Patient Safety in Respondents’ Countries, by WHO Region.

.... 18 Table 3.4 Top Five Clinical Care Safety Issues in Stakeholders’ Countries, by WHO Region

Table 3.5 Top Five System Process Safety Issues in Respondents’ Countries, by WHO Region

Table 3.6 Percentages of Field Review Respondents Who Strongly Agreed that the Solution Topic Is Relevant to Health Care Services in Their Country

Table 3.7 Patient Safety Solutions Rated by Survey Respondents As Extremely Relevant to Their Countries Priorities, by Region

Table 3.8 Availability of Additional Information on Patient Safety, Reported by Survey Respondents, by Region

Table 3.9 Percentages of Field Review Respondents Providing Comments on Each Patient Safety Solution

Table 3.10 Confidence of Survey Respondents in the Scientific Integrity of the Patient Safety Solutions

Table 3.11 Usefulness of the Patient Safety Solutions Products to Survey Respondents.

.......... 31 Table 4.1 Implementation of the Dissemination Plan for the Patient Safety Solutions............... 39 Table 4.2 Reported Patient Safety Solutions Hits on the Collaborating Centre Website, May 2007-July 2008

Table 4.3 Methods of Dissemination of the Patient Safety Solutions, As Reported by Survey Respondents for Their Countries

v Table 4.4 Awareness of the Patient Safety Solutions Reported by Survey Respondents, by Region

Table 4.5 How Survey Respondents First Became Aware of the Patient Safety Solutions.

....... 45 Table 4.6 Reported Use of the Patient Safety Solutions by Countries and Regions

Table 4.7 Uses and Adaptations of the Patient Safety Solutions by Survey Respondents That Used Them

Table 4.8 Issues that Prevented Survey Respondents from Using the Patient Safety Solutions 49 Table 4.

9 Estimates by Survey Respondents of How Much Each Patient Safety Solution Helped Other Organizations Achieve Safety Improvements

Table 5.1 Suggestions by the Survey Respondents for Improvements to the Patient Safety Solutions

–  –  –

As described on the World Health Organization (WHO) patient safety website,1 ―Patient Safety Solutions Aides memoir describe ―…system designs or interventions that demonstrate the ability to prevent or mitigate patient harm stemming from the processes of health care.‖ WHO established the goal to establish a set of Patient Safety Solutions Aides memoir (hereinafter called Solutions) that were evidence-based, presented in a standard format, and described in simple terms the actions to take to address risks associated with a particular patient safety problem. Each written Solution was to present the relevant problem and characterize the strength of evidence supporting actions to address it, including potential barriers to adoption, risks of unintended consequences created by the solution, and patient and family roles in the solution. In addition, each Solution was to cite relevant references and other resources.

In 2005, the World Health Organization (WHO) designated the Joint Commission and Joint Commission International as the WHO Collaborating Centre for Patient Safety Solutions.

Working with WHO, and with guidance from an International Steering Committee, the Collaborating Centre developed the first set of nine Patient Safety Solutions.

The Inaugural Set of Patient Safety Solutions Aides Memoir In April 2007, the inaugural set of Solutions was approved by the International Steering Committee for publication and dissemination, for use by WHO Member States as of May 2007.

The Solutions were posted on the websites of both WHO and the Collaborating Centre. 2 The

following are brief descriptions of topics for the nine Solutions:

 Look-Alike, Sound-Alike Medication Names. Confusing drug names is one of the most common causes of medication errors and is a worldwide concern. With tens of thousands of drugs currently on the market, the potential for error created by confusing brand or generic drug names and packaging is significant  Patient Identification. The widespread and continuing failures to correctly identify patients often leads to medication, transfusion and testing errors; wrong person procedures; and the discharge of infants to the wrong families.

 Communication During Patient Hand-Overs. Gaps in hand-over (or hand-off) communication between patient care units, and between and among care teams, can cause serious breakdowns in the continuity of care, inappropriate treatment, and potential harm for the patient.

 Performance of Correct Procedure at Correct Body Site. Considered totally preventable, cases of wrong procedure or wrong site surgery are largely the result of miscommunication and unavailable, or incorrect, information. A major contributing factor to these types of errors is the lack of a standardized preoperative process.

At http://www.who.int/patientsafety/implementation/solutions/patientsafety/solutions_explained/en/index.html.

At http://www.ccforpatientsafety.org/Patient-Safety-Solutions/.

 Control of Concentrated Electrolyte Solutions. While all drugs, biologics, vaccines and contrast media have a defined risk profile, concentrated electrolyte solutions that are used for injection are especially dangerous.

 Assuring Medication Accuracy at Transitions in Care. Medication errors occur most commonly at transitions. Medication reconciliation is a process designed to prevent medication errors at patient transition points.

 Avoiding Catheter and Tubing Mis-Connections. The design of tubing, catheters, and syringes currently in use is such that it is possible to inadvertently cause patient harm through connecting the wrong syringes and tubing and then delivering medication or fluids through an unintended wrong route.

 Single Use of Injection Devices. One of the biggest global concerns is the spread of Human Immunodeficiency Virus (HIV), the Hepatitis B Virus (HBV), and the Hepatitis C Virus (HCV) because of the reuse of injection needles.

 Improved Hand Hygiene to Prevent Health Care-Associated Infections. It is estimated that at any point in time more than 1.4 million people worldwide are suffering from infections acquired in hospitals. Effective hand hygiene is the primary preventive measure for avoiding this problem.

–  –  –

The Collaborative Network The set of Patient Safety Solutions Aides memoir was one of the first products developed by the Collaborating Centre. These Solutions were to address patient safety issues that were a shared priority of countries around the world. To guide the development work, the Collaborating Centre established and worked with a collaborative network of stakeholders. With the release of the set of nine Solutions in May 2007, WHO and the Collaborating Centre then began a dissemination process to inform stakeholders about their availability and what they contained.

The collaborative network consisted of an International Steering Committee, three Regional Advisory Councils, and three expert panels that served as technical resources to the network.

Each of these bodies met regularly and were staffed by the Collaborating Centre staff.

International Steering Committee. Experts from leading patient safety organizations around the world were asked to serve on the Steering Committee, which had the overall responsibility of selecting the priority patient safety issues to be addressed by the Solutions and guiding development of those Solutions products. With a membership of 40 individuals, the Steering Committee broadly represented countries in all six of the WHO regions.

Regional Advisory Councils. These Councils were a mechanism to obtain feedback on the work on the Solutions emanating from the Steering Committee. Their role was to communicate the specific needs of the regions—and countries within them—to be taken into consideration during the Solutions prioritization, development, and dissemination process. Three Councils were established: Asia-Pacific Council, Middle East and North Africa Council, and Europe Council.

A representative from Israel serves on the Europe Council. Although the Collaborating Centre had hoped to establish similar Councils in Africa and South America, this was not possible because of funding limitations. However, North Africa was represented on the Middle East and North Africa Council, and South America was represented on the International Steering Committee.

According to the Collaborating Centre staff, the Steering Committee sought feedback from the Regional Advisory Councils to gain the perspectives of the different regions on patient safety priorities and the Solutions products. The Councils helped drill down details of the Solutions during development, and also provided leadership in dissemination of the Solutions, once released. In addition, the Council meetings have been a source of information on how countries have been using the Solutions, by inviting Council members to do presentations on the state of patient safety in their countries and their use of the Solutions.

Pages:   || 2 | 3 | 4 | 5 |   ...   | 9 |

Similar works:

«Prabhat, P., Ram, S., Ward, E. S., and Ober, R. J. Simultaneous imaging of several focal planes in fluorescence microscopy for the study of cellular dynamics in 3D. In Three-Dimensional and Multidimensional Microscopy: Image Acquisition and Processing XIII. SPIE the International Society for Optical Engineering, 6090: 6090-0L, 2006. Copyright 2009 Society of Photo-Optical Instrumentation Engineers. One print or electronic copy may be made for personal use only. Systematic reproduction and...»

«How Acupuncture works? Neuroscientific basis underlying Acupuncture Analgesia Chinese Acupuncture Association 4353 Midmost Drive,Mobile, AL 36609 Xue Cui Xiang OMD,Peter Zhang MD The mechanism of acupuncture analgesia and health care remains unclear,though it has been used for the treatment of pain and disease over 3,000 years in China. In the past half century,modern medical science findings,particularly fMRI findings have Opened a new access to get insight into the mystery mechanism of...»

«78732XX CAPSULES CUPRIMINE® (PENICILLAMINE) Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity.DESCRIPTION Penicillamine is a chelating agent used in the treatment of Wilson's disease....»

«FDA Briefing Package Table of Contents I. Division Memorandum II. Clinical Briefing Document III. Statistical Briefing Document IV. Clinical Pharmacology Summary V. Immunoassay Summary VI. Bibliography DIVISION MEMORANDUM Date: January 9, 2009 From: Sally Seymour, MD Deputy Director for Safety, Division of Pulmonary and Allergy Products To: Members, Pulmonary-Allergy Drugs Advisory Committee Subject: Overview of the FDA background materials for BLA# 125277, Kalbitor (ecallantide)...»

«Aquaware Intent Index INTENTS I  Bathing & Showering  Human Potential Bathing & Showering  Abdominal Gas – gas and bloating  Acne – cell regeneration, chemical normalization, cleanse, open pores  Adventurer & Athletic Performance – increase energy, strength, speed, endurance, healing & decrease fear + protection against physical danger  Allergies – symptoms and causations  Arthritis – symptoms and causations  Attention Deficit – intensity and duration of...»

«INDICATORS OF FINANCIAL SOLVENCY IN U.S. HOSPITALS AND HEALTH SYSTEMS: A SYSTEMATIC REVIEW OF THE LITERATURE By Amy V. Semritc A thesis submitted in partial fulfillment of the requirements for the degree of MASTER OF HEALTH POLICY AND ADMINISTRATION WASHINGTON STATE UNIVERSITY Department of Health Policy and Administration MAY 2009 To the Faculty of Washington State University: The members of the Committee appointed to examine the thesis of AMY V. SEMRITC find it satisfactory and recommend that...»

«JBC Papers in Press. Published on May 16, 2001 as Manuscript M103092200 Segev et al., Page 1 Müllerian Inhibiting Substance Regulates NFkB Signaling and Growth of Mammary Epithelial Cells Dorry L. Segev, Yasunori Hoshiya, Antonia E. Stephen, Makiko Hoshiya, Trinh T. Tran, David T. MacLaughlin, Patricia K. Donahoe and Shyamala Maheswaran Pediatric Surgical Research Laboratories, Massachusetts General Hospital and Harvard Medical Downloaded from http://www.jbc.org/ by guest on November 26, 2016...»

«Draft TSD for Noncancer RELs, SRP4 September 2008 Acetaldehyde Reference Exposure Levels (ethanal; acetic aldehyde; acetylaldehyde; ethylaldehyde; diethylacetyl) CAS: 75-07-0 1. Summary Based on acute and chronic inhalation studies conducted mostly in experimental animals, the target tissue for acetaldehyde has consistently been at the portal of entry with effects occurring primarily in the upper respiratory tract at lowest concentrations. The major noncancer health effects of acute exposure in...»

«Br. J. Pharmac. (1969), 37, 733-737. Carbon tetrachloride metabolism in the rabbit J. S. L. FOWLER Department of Veterinary Pharmacology, Royal (Dick) School of Veterinary Studies, Edinburgh 9 1. Carbon tetrachloride was administered by stomach tube to rabbits and its distribution in fat, liver, kidney and muscle studied by gas liquid chromatography, during the next 48 hr.2. Chloroform, hexachloroethane and two unidentified chlorinated metabolites were detected in the tissues. 3....»

«21 July 2016 EMA/CHMP/BWP/532517/2008 Committee for medicinal products for human use (CHMP) Guideline on development, production, characterisation and specification for monoclonal antibodies and related products 3R’s technical update January 2016 Agreed by Biologics Working Party January 2016 Adopted by CHMP July 2016 Date for coming into effect September 2016 * This is a technical update to reflect current best practice with regard to implementation of 3Rs approaches and it is not intended...»

«Department of Employee Trust Funds State Agency Health Insurance Administration Manual Chapter 9 – COBRA, Continuation and Conversion 901 Overview of COBRA, Continuation and Conversion 902 Persons Eligible for Continuation (Qualified Beneficiaries) 903 Employee Responsibilities 904 Qualified Beneficiary Responsibilities 905 Employer Responsibilities 906 Notice Requirement Illustration Chart 907 Continuation Coverage Information 901 Overview of COBRA, Continuation and Conversion Under the...»

«_Essay _ Are Organ Transplants Ever Morally Licit? A commentary on the address of Pope John Paul II to the XVIII International Congress of the Transplantation Society By Bishop Fabian Wendelin Bruskewitz, Bishop Robert F. Vasa, Walt F. Weaver, Paul A. Byrne, Richard G. Nilges, and Josef Seifert On August 29, 2000, Pope John Paul II delivered an address to the XVIII International Congress of the Transplantation Society. While we are grateful for his teachings, we believe that certain points...»

<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.